Isocitrate dehydrogenase inhibitor‐driven differentiation may resemble secondary graft failure in post‐allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia
暂无分享,去创建一个
P. Ferrell | S. Strickland | E. Mason | Adrianne Rasche | Michael T Byrne | Michael T. Byrne | Emily F. Mason | M. Byrne
[1] S. Choe,et al. A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML. , 2021, Blood advances.
[2] G. Lip,et al. Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials , 2021, medRxiv.
[3] Matthew J. Frigault,et al. A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2-Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation , 2020, Blood.
[4] D. Jiménez,et al. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019 , 2020, Chest.
[5] F. de Cobelli,et al. Spontaneous Major Hemorrhage in COVID-19 Patients: Another Brick in the Wall of SARS-CoV-2–Associated Coagulation Disorders? , 2020, Journal of Vascular and Interventional Radiology.
[6] Y. Kanthi,et al. COVID–19-associated coagulopathy: An exploration of mechanisms , 2020, Vascular medicine.
[7] S. Lane,et al. Thromboprophylaxis in COVID-19: Anti-FXa—the Missing Factor? , 2020, American journal of respiratory and critical care medicine.
[8] R. Jayani,et al. The use of venetoclax‐based salvage therapy for post‐hematopoietic cell transplantation relapse of acute myeloid leukemia , 2020, American journal of hematology.
[9] Mickaël Ohana,et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.
[10] D. King,et al. Spontaneous Retroperitoneal and Rectus Sheath Hemorrhage—Management, Risk Factors and Outcomes , 2019, World Journal of Surgery.
[11] R. Collins,et al. Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.
[12] P. Vyas,et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. , 2017, Blood.
[13] I. Flinn,et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.
[14] C. Dinardo,et al. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. , 2016, Clinical lymphoma, myeloma & leukemia.
[15] Daniel Cabrera,et al. Spontaneous retroperitoneal hematoma: etiology, characteristics, management, and outcome. , 2012, The Journal of emergency medicine.
[16] A. Segado Soriano,et al. [Spontaneous retroperitoneal hemorrhage]. , 1995, Anales de medicina interna.
[17] M. A. Tomlinson,et al. Retroperitoneal haematoma. , 2000, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.